Morgan Stanley Reiterates Overweight on Inari Medical, Maintains $83 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong has reiterated an Overweight rating on Inari Medical (NASDAQ:NARI) and maintained a price target of $83.
August 04, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Inari Medical, maintaining a price target of $83.
The reiteration of an Overweight rating by a major financial institution like Morgan Stanley indicates a positive outlook for Inari Medical. The maintained price target of $83 also suggests that the analyst believes the stock is currently undervalued, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100